報價延遲最少15分鐘:2024/12/24 12:40 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-11.69/-8.12
|
|
企業價值
1.70M
|
| 資產負債 |
|
每股賬面淨值
3.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
1.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 12:40 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States. |